ADVM · As filed with the SEC
Adverum Biotechnologies cash flow statement, by fiscal year
The statement as Adverum Biotechnologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 | FY2017 Year ended Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net loss | — | — | — | — | — | (64,486,000) | (72,627,000) | — |
| Net loss | (130,927) | (117,165) | (154,536) | (145,540) | (117,507) | — | — | (56,147) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 3,653 | 5,644 | 6,528 | 4,645 | 4,158 | 1,573 | 1,750 | 2,096 |
| Stock-based compensation expense | 14,350 | 17,569 | 20,079 | 25,194 | 20,391 | 9,899 | 13,432 | 8,723 |
| Net accretion of discount on marketable securities | (1,907) | (1,935) | (880) | 2,770 | 521 | (1,273) | 24 | 593 |
| Accreted interest on BPI | — | — | — | 0 | 17 | 22 | 95 | — |
| Impairment of goodwill and intangible assets | — | — | — | — | 0 | — | 5,000 | — |
| Non-cash research and development expense | — | — | — | — | — | — | — | 60,000 |
| Non-cash lease expense | 7,495 | 13,027 | — | — | — | — | — | — |
| Non-cash sublease loss/(income) | 14,000 | — | — | — | — | — | — | — |
| Loss on disposal of property and equipment | 2 | 50 | 122 | — | — | — | — | — |
| Impairment of long-lived assets | — | 224 | 2,124 | 1,063 | — | — | — | — |
| Foreign currency remeasurement loss | — | — | — | 0 | 342 | — | — | — |
| Other | (39) | 1 | (1,417) | (25) | 58 | 36 | (17) | 10 |
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | — | — | — | — | — | — | — | 886,000 |
| Prepaid expenses and other current assets | 638 | 298 | 1,653 | (2,257) | 5,854 | (5,954) | (793) | (491) |
| Deposit and other long-term assets and deferred rent receivable | — | 182 | (394) | (990) | — | — | — | — |
| Operating lease right-of-use assets | — | — | 4,040 | 2,719 | 1,587 | 2,168 | — | — |
| Deposit and other long-term assets | (68) | — | — | — | (18) | — | (16) | — |
| Accounts payable | (262) | (369) | 845 | (1,612) | 1,585 | (650) | (67) | 333 |
| Accrued expenses and other liabilities | 3,021 | (5,206) | 64 | 3,274 | 4,147 | 1,909 | 215 | 487 |
| Restructuring liabilities | — | — | — | — | — | — | — | (25,000) |
| Deferred revenue | — | — | — | — | — | — | — | (1,849,000) |
| Deferred revenue | — | — | — | — | 0 | — | (953) | — |
| Deferred rent | — | — | — | — | 0 | — | 1,243 | (97) |
| Net cash used in operating activities | — | — | — | — | — | — | — | (45,421,000) |
| Other non-current liabilities | — | — | 74 | 0 | 1,114 | — | — | — |
| Lease liability | — | — | — | — | (1,540) | 7,586 | — | — |
| Deferred tax liability | — | — | — | — | 0 | — | (1,250) | — |
| Lease liability | (2,418) | (3,222) | 13,607 | 2,928 | — | — | — | — |
| Net cash used in operating activities | (92,462) | (90,902) | (108,091) | (107,831) | (79,291) | (49,170) | (53,964) | — |
| Cash flows from investing activities: | ||||||||
| Purchases of marketable securities | — | — | — | — | — | — | (78,726,000) | (209,787,000) |
| Sales of marketable securities | — | — | — | — | — | — | — | 1,003,000 |
| Purchases of marketable securities | (101,901) | (36,718) | (104,363) | (407,514) | (570,386) | (197,343) | — | — |
| Maturities of marketable securities | 60,400 | 134,401 | 257,899 | 492,356 | 295,315 | 148,517 | 148,979 | 87,596 |
| Sales of marketable securities | — | — | 0 | 8,990 | 6,748 | — | — | — |
| Purchases of property and equipment | (388) | (808) | (11,816) | (15,123) | (11,844) | (19,247) | (809) | (1,016) |
| Net cash (used in) provided by investing activities | — | — | — | — | — | — | — | (122,204,000) |
| Net cash (used in) provided by investing activities | (41,889) | 96,875 | 141,720 | 78,709 | (280,167) | (68,073) | 69,444 | — |
| Cash flows from financing activities: | ||||||||
| Proceeds from offering of common stock, net of issuance costs | — | — | 0 | 1,685 | 344,302 | 25,755 | 70,187 | 16,519 |
| Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs | 119,361 | — | — | — | 0 | 134 | — | — |
| Payment of deferred offering costs | 0 | (420) | — | — | — | — | — | — |
| Proceeds from issuance of common stock pursuant to option exercises | 146 | 1 | 3 | 51 | 12,687 | 3,442 | 688 | 367 |
| Taxes paid related to net share settlement of restricted stock units | — | — | — | 0 | (2,043) | (1,470) | (1,191) | (313) |
| Proceeds from employee stock purchase plan | 496 | 488 | 604 | 901 | 1,100 | 442 | 340 | 175 |
| Repayment of BPI loan | — | — | 0 | (240) | (61) | (112) | (175) | — |
| Proceeds from a financing arrangement | — | — | — | — | 0 | — | 100 | — |
| Net cash provided by financing activities | — | — | — | — | — | — | — | 16,748,000 |
| Effect of foreign currency exchange rate on cash and cash equivalents | — | — | — | — | — | — | — | (774,000) |
| Net (decrease) increase in cash and cash equivalents | — | — | — | — | — | — | — | (151,651,000) |
| Cash and cash equivalents at beginning of period | — | — | — | — | — | — | 70,519,000 | 222,170,000 |
| Cash and cash equivalents at end of period | — | — | — | — | — | — | — | 70,519,000 |
| Net cash provided by financing activities | 120,003 | 69 | 607 | 2,397 | 355,985 | 28,191 | 69,949 | — |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (14,348) | 6,042 | 34,236 | (26,725) | (3,473) | (89,052) | 85,429 | — |
| Cash and cash equivalents and restricted cash at beginning of period | — | — | 36,698 | 63,423 | 66,896 | 155,948 | 70,519 | — |
| Cash and cash equivalents and restricted cash at end of period | — | — | — | 36,698 | 63,423 | 66,896 | 155,948 | — |
| Cash, cash equivalents and restricted cash at beginning of period | 76,976 | 70,934 | 36,698 | — | — | — | — | — |
| Cash, cash equivalents and restricted cash at end of period | 62,628 | 76,976 | 70,934 | — | — | — | — | — |
| Supplemental schedule of noncash information | ||||||||
| Right-of-use assets obtained in exchange for lease liability | — | — | 0 | 84,005 | — | — | — | — |
| Decrease in right-of-use asset and lease liability due to termination | — | — | 0 | 15,768 | — | — | — | — |
| Remeasurement of right-of-use asset on lease modification | — | — | 2,842 | 2,052 | — | — | — | — |
| Remeasurement of operating lease right-of-use assets and liabilities | 0 | 13,711 | — | — | — | — | — | — |
| Fixed assets in accounts payable and current liabilities | 201 | 91 | 64 | 1,402 | 403 | 5,242 | 1,616 | 115 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.